GB9315856D0
(en)
*
|
1993-07-30 |
1993-09-15 |
Wellcome Found |
Stabilized pharmaceutical
|
US5541231A
(en)
*
|
1993-07-30 |
1996-07-30 |
Glaxo Wellcome Inc. |
Stabilized Pharmaceutical
|
US5616344A
(en)
*
|
1994-06-14 |
1997-04-01 |
Fuisz Technologies Ltd. |
Apparatus and process for strengthening low density compression dosage units and product therefrom
|
HU226583B1
(hu)
*
|
1997-09-25 |
2009-04-28 |
Bayer Ag |
Moxifloxacint tartalmazó szabályozott hatóanyag-leadású gyógyászati készítmények
|
US6221917B1
(en)
|
1997-12-30 |
2001-04-24 |
American Home Products Corporation |
Pharmaceutical composition containing bupropion hydrochloride and a stabilizer
|
US5968553A
(en)
*
|
1997-12-30 |
1999-10-19 |
American Home Products Corporation |
Pharmaceutical composition containing bupropion hydrochloride and an inorganic acid stabilizer
|
US7098206B2
(en)
*
|
1998-01-21 |
2006-08-29 |
Smithkline Beecham Corporation |
Pharmaceutically active morpholinol
|
US6998400B2
(en)
*
|
1998-01-22 |
2006-02-14 |
Smithkline Beecham Corporation |
Pharmaceutically active morpholinol
|
JP2002501892A
(ja)
*
|
1998-01-29 |
2002-01-22 |
セプラコア インコーポレーテッド |
光学的に純粋な(−)−ビュープロピオンの薬学的使用
|
EP1051166A1
(en)
*
|
1998-01-29 |
2000-11-15 |
Sepracor, Inc. |
Pharmaceutical uses of optically pure (+) -bupropion
|
WO1999038499A2
(en)
*
|
1998-01-29 |
1999-08-05 |
Sepracor Inc. |
Methods and compositions for aiding in smoking cessation and for treating pain and other disorders using optically pure (-)-bupropion
|
AU2349999A
(en)
*
|
1998-01-29 |
1999-08-16 |
Sepracor, Inc. |
Pharmacological uses of pure (+) -bupropion
|
US6150420A
(en)
*
|
1998-06-01 |
2000-11-21 |
Theramax, Inc. |
Method for enhanced brain delivery of bupropion
|
US6153223A
(en)
*
|
1998-06-05 |
2000-11-28 |
Watson Pharmaceuticals, Inc. |
Stabilized pharmaceutical compositions
|
US6096341A
(en)
*
|
1998-10-30 |
2000-08-01 |
Pharma Pass Llc |
Delayed release tablet of bupropion hydrochloride
|
US6033686A
(en)
*
|
1998-10-30 |
2000-03-07 |
Pharma Pass Llc |
Controlled release tablet of bupropion hydrochloride
|
US6238697B1
(en)
*
|
1998-12-21 |
2001-05-29 |
Pharmalogix, Inc. |
Methods and formulations for making bupropion hydrochloride tablets using direct compression
|
US6855820B2
(en)
|
1999-01-20 |
2005-02-15 |
Smithkline Beecham Corporation |
Pharmaceutically active morpholinol
|
US6734213B2
(en)
|
1999-01-20 |
2004-05-11 |
Smithkline Beecham Corporation |
Pharmaceutically active morpholinol
|
US8545880B2
(en)
*
|
1999-02-26 |
2013-10-01 |
Andrx Pharmaceuticals, Llc |
Controlled release oral dosage form
|
US6589553B2
(en)
*
|
2001-02-08 |
2003-07-08 |
Andrx Pharmaceuticals, Inc. |
Controlled release oral dosage form
|
US6210716B1
(en)
*
|
1999-02-26 |
2001-04-03 |
Andrx Pharmaceuticals, Inc. |
Controlled release bupropion formulation
|
US6337328B1
(en)
*
|
1999-03-01 |
2002-01-08 |
Sepracor, Inc. |
Bupropion metabolites and methods of use
|
US6342496B1
(en)
*
|
1999-03-01 |
2002-01-29 |
Sepracor Inc. |
Bupropion metabolites and methods of use
|
USD430285S
(en)
*
|
1999-04-16 |
2000-08-29 |
Merck & Co., Inc. |
Tablet
|
US6280763B1
(en)
|
1999-05-10 |
2001-08-28 |
Pierce Management, Llc |
Apparatus and method for transdermal delivery of bupropion
|
IL149421A0
(en)
*
|
1999-11-02 |
2002-11-10 |
Depomed Inc |
Pharmaceutical compositions containing fed mode inducing agents
|
US6306436B1
(en)
|
2000-04-28 |
2001-10-23 |
Teva Pharmaceuticals Usa, Inc. |
Stabilized, acid-free formulation for sustained release of bupropion hydrochloride
|
CA2685214C
(en)
*
|
2001-02-08 |
2013-01-22 |
Andrx Pharmaceuticals, Inc. |
Improved controlled release oral dosage form
|
ITMI20011457A1
(it)
*
|
2001-07-09 |
2003-01-09 |
Valpharma Sa |
Composizione farmaceutica a rilascio modificato contenente bupropionehc1 come sostanza attiva
|
US20030044462A1
(en)
*
|
2001-08-20 |
2003-03-06 |
Kali Laboratories, Inc. |
Sustained release tablets containing bupropion hydrochloride
|
CN1649614A
(zh)
|
2002-02-22 |
2005-08-03 |
新河药品股份有限公司 |
活性剂传递系统和保护及施用活性剂的方法
|
US20050215552A1
(en)
*
|
2002-05-17 |
2005-09-29 |
Gadde Kishore M |
Method for treating obesity
|
KR20110043664A
(ko)
*
|
2002-05-17 |
2011-04-27 |
듀크 유니버시티 |
비만치료방법
|
US7776314B2
(en)
|
2002-06-17 |
2010-08-17 |
Grunenthal Gmbh |
Abuse-proofed dosage system
|
WO2004041244A2
(en)
*
|
2002-10-30 |
2004-05-21 |
Pharmacia Corporation |
Oral extended release tablets and methods of making and using the same
|
US20040096497A1
(en)
*
|
2002-11-19 |
2004-05-20 |
Ponder Garratt W. |
Methods of providing controlled-release pharmaceutical compositions and controlled-release pharmaceutical compositions
|
US6893660B2
(en)
*
|
2002-11-21 |
2005-05-17 |
Andrx Pharmaceuticals, Inc. |
Stable pharmaceutical compositions without a stabilizer
|
PT2316456T
(pt)
*
|
2003-04-29 |
2017-09-05 |
Orexigen Therapeutics Inc |
Composições para afetar a perda de peso compreendendo naltrexona e bupropion
|
DE102004032051A1
(de)
*
|
2004-07-01 |
2006-01-19 |
Grünenthal GmbH |
Verfahren zur Herstellung einer gegen Missbrauch gesicherten, festen Darreichungsform
|
DE10336400A1
(de)
|
2003-08-06 |
2005-03-24 |
Grünenthal GmbH |
Gegen Missbrauch gesicherte Darreichungsform
|
DE102005005446A1
(de)
|
2005-02-04 |
2006-08-10 |
Grünenthal GmbH |
Bruchfeste Darreichungsformen mit retardierter Freisetzung
|
DE10361596A1
(de)
|
2003-12-24 |
2005-09-29 |
Grünenthal GmbH |
Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
|
US8075872B2
(en)
*
|
2003-08-06 |
2011-12-13 |
Gruenenthal Gmbh |
Abuse-proofed dosage form
|
US20070048228A1
(en)
|
2003-08-06 |
2007-03-01 |
Elisabeth Arkenau-Maric |
Abuse-proofed dosage form
|
DE60330909D1
(de)
*
|
2003-08-08 |
2010-02-25 |
Biovail Lab Int Srl |
Tablette mit modifizierter freisetzung von bupropion hydrochlorid
|
US7713959B2
(en)
|
2004-01-13 |
2010-05-11 |
Duke University |
Compositions of an anticonvulsant and mirtazapine to prevent weight gain
|
US20060160750A1
(en)
*
|
2004-01-13 |
2006-07-20 |
Krishnan K R R |
Compositions of an anticonvulsant and an antipsychotic drug and methods of using the same for affecting weight loss
|
WO2005070461A2
(en)
|
2004-01-13 |
2005-08-04 |
Duke University |
Compositions of an anticonvulsant and an antipsychotic drug for affecting weight loss
|
WO2005107806A1
(en)
*
|
2004-04-21 |
2005-11-17 |
Orexigen Therapeutics, Inc. |
Compositions for affecting weight loss
|
DE102004032049A1
(de)
|
2004-07-01 |
2006-01-19 |
Grünenthal GmbH |
Gegen Missbrauch gesicherte, orale Darreichungsform
|
US8586085B2
(en)
|
2004-11-08 |
2013-11-19 |
Biokey, Inc. |
Methods and formulations for making pharmaceutical compositions containing bupropion
|
US20060099262A1
(en)
*
|
2004-11-08 |
2006-05-11 |
Biokey, Inc. |
Methods and formulations for making controlled release oral dosage form
|
GB0425445D0
(en)
*
|
2004-11-18 |
2004-12-22 |
Smithkline Beecham Corp |
Novel compositions
|
KR100670798B1
(ko)
|
2004-12-17 |
2007-01-17 |
한국전자통신연구원 |
데이터베이스 캐시 시스템
|
DE102005005449A1
(de)
|
2005-02-04 |
2006-08-10 |
Grünenthal GmbH |
Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
|
CA2578626C
(en)
*
|
2005-06-27 |
2011-07-19 |
Biovail Laboratories International S.R.L. |
Modified-release formulations of a bupropion salt
|
JP2009511607A
(ja)
*
|
2005-10-14 |
2009-03-19 |
ハー・ルンドベック・アクチエゼルスカベット |
エスシタロプラムおよびブプロピオンを含有する安定な医薬製剤
|
EP1954257A4
(en)
*
|
2005-10-14 |
2009-05-20 |
Lundbeck & Co As H |
METHOD FOR TREATING DISORDERS OF THE CENTRAL NERVOUS SYSTEM WITH A LOW-DOSED COMBINATION OF ESCITALOPRAM AND BUPROPION
|
CN101370488B
(zh)
|
2005-11-22 |
2012-07-18 |
奥雷西根治疗公司 |
增加胰岛素敏感性的组合物
|
JP2009517394A
(ja)
*
|
2005-11-28 |
2009-04-30 |
オレキシジェン・セラピューティクス・インコーポレーテッド |
ゾニサミドの徐放性製剤
|
CA2638734A1
(en)
*
|
2006-02-27 |
2007-09-07 |
The Board Of Trustees Of The Leland Stanford Junior University |
Inhibitors of the unfolded protein response and methods for their use
|
CA2644851A1
(en)
|
2006-03-07 |
2007-09-13 |
Osteoscreen Ip, Llc |
Hmg co-a reductase inhibitor enhancement of bone and cartilage
|
US8916195B2
(en)
|
2006-06-05 |
2014-12-23 |
Orexigen Therapeutics, Inc. |
Sustained release formulation of naltrexone
|
WO2008042480A2
(en)
|
2006-06-13 |
2008-04-10 |
The Board Of Trustees Of The Leland Stanford Junior University |
Epoxide inhibitors of cysteine proteases
|
US8703191B2
(en)
*
|
2006-07-25 |
2014-04-22 |
Intelgenx Corp. |
Controlled-release pharmaceutical tablets
|
US7674479B2
(en)
*
|
2006-07-25 |
2010-03-09 |
Intelgenx Corp. |
Sustained-release bupropion and bupropion/mecamylamine tablets
|
BRPI0715959A2
(pt)
*
|
2006-08-21 |
2013-07-30 |
Jubilant Organosys Ltd |
composiÇço farmacÊutica de liberaÇço modificada de cloridrato de bupropion
|
ATE460925T1
(de)
|
2006-11-09 |
2010-04-15 |
Orexigen Therapeutics Inc |
Mehrschichtige pharmazeutische formulierungen mit einer schnell auflösenden zwischenschicht
|
MX2009004871A
(es)
|
2006-11-09 |
2009-06-16 |
Orexigen Therapeutics Inc |
Paquete de dosificacion unitaria y metodos para administrar medicaciones de perdida de peso.
|
DE102007011485A1
(de)
|
2007-03-07 |
2008-09-11 |
Grünenthal GmbH |
Darreichungsform mit erschwertem Missbrauch
|
WO2008124128A2
(en)
|
2007-04-09 |
2008-10-16 |
Sepracor Inc. |
Methods and compositions comprising desvenlafaxine or duloxetine for treating sleep-related breathing disorders
|
AU2008266906A1
(en)
*
|
2007-06-18 |
2008-12-24 |
The General Hospital Corporation |
Combination therapy for depression
|
US20090162434A1
(en)
*
|
2007-12-21 |
2009-06-25 |
Disphar International Bv |
Mesalazine tablet
|
NZ586792A
(en)
|
2008-01-25 |
2012-09-28 |
Gruenenthal Chemie |
Tamper resistant controlled release pharmaceutical tablets form having convex and concave surfaces
|
WO2009111031A2
(en)
|
2008-03-04 |
2009-09-11 |
Intra-Cellular Therapies, Inc. |
Methods of treating vasomotor symptoms
|
PT2273983T
(pt)
|
2008-05-09 |
2016-10-28 |
Gruenenthal Gmbh |
Processo para a preparação de uma formulação em pó intermediária e uma forma de dosagem sólida final sob utilização de uma etapa de congelamento por atomização
|
JP2011521973A
(ja)
|
2008-05-30 |
2011-07-28 |
オレキシジェン・セラピューティクス・インコーポレーテッド |
内臓脂肪の状態を処置するための方法
|
TW201039815A
(en)
|
2009-04-13 |
2010-11-16 |
Resolvyx Pharmaceuticals Inc |
Compositions and methods for the treatment of inflammation
|
SI2456424T1
(sl)
|
2009-07-22 |
2013-10-30 |
Gruenenthal Gmbh |
Oksidacijsko stabilizirana odmerna oblika, varna pred zlorabo
|
AU2010275753B2
(en)
*
|
2009-07-22 |
2014-08-21 |
Grünenthal GmbH |
Hot-melt extruded controlled release dosage form
|
US10610528B2
(en)
|
2009-12-08 |
2020-04-07 |
Intelgenx Corp. |
Solid oral film dosage forms and methods for making same
|
US20110136815A1
(en)
|
2009-12-08 |
2011-06-09 |
Horst Zerbe |
Solid oral film dosage forms and methods for making same
|
BR112012016783A2
(pt)
|
2010-01-11 |
2015-09-01 |
Orexigen Therapeutics Inc |
"usos do composto de naltrexona ou sal farmaceuticamente aceitável da mesma a bupropiona ou sal farmaceuticamente aceitável da mesma ou de composição dos mesmos e métodos para proporcionar terapia"
|
EP2531176B1
(en)
|
2010-02-03 |
2016-09-07 |
Grünenthal GmbH |
Preparation of a powdery pharmaceutical composition by means of an extruder
|
WO2012028319A1
(en)
|
2010-09-02 |
2012-03-08 |
Grünenthal GmbH |
Tamper resistant dosage form comprising inorganic salt
|
KR20130137627A
(ko)
|
2010-09-02 |
2013-12-17 |
그뤼넨탈 게엠베하 |
음이온성 중합체를 포함하는 내변조성 투여형
|
EP2627324A4
(en)
|
2010-10-11 |
2014-05-07 |
Univ Leland Stanford Junior |
SUBSTITUTED BENZAMIDES AND USES THEREOF
|
SI2632927T1
(sl)
|
2010-10-26 |
2016-08-31 |
Mars, Incorporated |
Boronati kot inhibitorji arginaze
|
EP2736497B1
(en)
|
2011-07-29 |
2017-08-23 |
Grünenthal GmbH |
Tamper-resistant tablet providing immediate drug release
|
US10201502B2
(en)
|
2011-07-29 |
2019-02-12 |
Gruenenthal Gmbh |
Tamper-resistant tablet providing immediate drug release
|
HUE047642T2
(hu)
|
2011-11-21 |
2020-05-28 |
Calithera Biosciences Inc |
A glutamináz heterociklusos gátlói
|
AU2013225106B2
(en)
|
2012-02-28 |
2017-11-02 |
Grunenthal Gmbh |
Tamper-resistant dosage form comprising pharmacologically active compound and anionic polymer
|
SG10201509063SA
(en)
|
2012-04-12 |
2015-12-30 |
Univ Leland Stanford Junior |
Substituted benzamides and their uses
|
ES2692944T3
(es)
|
2012-04-18 |
2018-12-05 |
Grünenthal GmbH |
Forma de dosificación farmacéutica resistente a la manipulación y resistente a la descarga rápida de la dosis
|
US10064945B2
(en)
|
2012-05-11 |
2018-09-04 |
Gruenenthal Gmbh |
Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
|
MA37714A1
(fr)
|
2012-06-06 |
2017-12-29 |
Orexigen Therapeutics Inc |
Méthodes de traitement de la surcharge pondérale et de l'obésité
|
CA2891667A1
(en)
|
2012-11-16 |
2014-05-22 |
Calithera Biosciences Inc. |
Heterocyclic glutaminase inhibitors
|
JP6490660B2
(ja)
|
2013-03-15 |
2019-03-27 |
ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー |
活性に基づくプローブの化合物、組成物、および使用方法
|
BR112015029616A2
(pt)
|
2013-05-29 |
2017-07-25 |
Gruenenthal Gmbh |
forma de dosagem resistente à adulteração com perfil de liberação bimodal
|
WO2014191397A1
(en)
|
2013-05-29 |
2014-12-04 |
Grünenthal GmbH |
Tamper-resistant dosage form containing one or more particles
|
MX368846B
(es)
|
2013-07-12 |
2019-10-18 |
Gruenenthal Gmbh |
Forma de dosificación resistente a la alteración que contiene polímero de acetato de etilen-vinilo.
|
CA2931553C
(en)
|
2013-11-26 |
2022-01-18 |
Grunenthal Gmbh |
Preparation of a powdery pharmaceutical composition by means of cryo-milling
|
CA2947786A1
(en)
|
2014-05-12 |
2015-11-19 |
Grunenthal Gmbh |
Tamper resistant immediate release capsule formulation comprising tapentadol
|
EP3148512A1
(en)
|
2014-05-26 |
2017-04-05 |
Grünenthal GmbH |
Multiparticles safeguarded against ethanolic dose-dumping
|
EA036001B1
(ru)
|
2014-06-13 |
2020-09-11 |
Калитера Байосайенсиз, Инк. |
Комбинация эрлотиниба и ингибитора глутаминазы для лечения рака легких
|
EA037738B1
(ru)
|
2014-08-07 |
2021-05-17 |
Калитера Байосайенсиз, Инк. |
Кристаллические формы ингибиторов глутаминазы
|
EP3180332B1
(en)
|
2014-08-13 |
2021-10-27 |
Eolas Therapeutics Inc. |
Difluoropyrrolidines as orexin receptor modulators
|
US20170333450A1
(en)
|
2014-10-31 |
2017-11-23 |
The Regents Of The University Of California |
Compositions and methods for treating hiv-associated cognitive dysfunction
|
ES2907988T3
(es)
|
2015-03-10 |
2022-04-27 |
Aurigene Discovery Tech Ltd |
Compuestos de 1,2,4-oxadiazol y tiadiazol como inmunomoduladores
|
EP3285745A1
(en)
|
2015-04-24 |
2018-02-28 |
Grünenthal GmbH |
Tamper-resistant dosage form with immediate release and resistance against solvent extraction
|
WO2016210106A1
(en)
|
2015-06-23 |
2016-12-29 |
Calithera Biosciences, Inc. |
Compositions and methods for inhibiting arginase activity
|
KR102305932B1
(ko)
|
2015-06-29 |
2021-09-28 |
플로로놀 인코퍼레이티드 |
갈조류의 고체 약제학적 조성물
|
CA2998259A1
(en)
|
2015-09-10 |
2017-03-16 |
Grunenthal Gmbh |
Protecting oral overdose with abuse deterrent immediate release formulations
|
GB2542881B
(en)
|
2015-10-02 |
2020-01-01 |
Carr Andrew |
Crystal forms of ß-nicotinamide mononucleotide
|
US10258619B2
(en)
|
2015-10-05 |
2019-04-16 |
Calithera Biosciences, Inc. |
Combination therapy with glutaminase inhibitors and immuno-oncology agents
|
MD3368541T2
(ro)
|
2015-10-30 |
2020-09-30 |
Calithera Biosciences Inc |
Compoziții și procedee de inhibare a activității arginazei
|
WO2017087517A1
(en)
|
2015-11-16 |
2017-05-26 |
Demeter Therapeutics, Llc |
Nucleic acid prodrugs
|
KR20180107232A
(ko)
|
2016-02-12 |
2018-10-01 |
아스트라제네카 아베 |
오렉신 수용체 조정제로서의 할로-치환된 피페리딘
|
WO2017210565A1
(en)
|
2016-06-03 |
2017-12-07 |
Prisident And Fellows Of Harvard College |
Antifungal compounds
|
WO2018039612A1
(en)
|
2016-08-26 |
2018-03-01 |
The Regents Of The University Of California |
Compositions and methods for promoting hair growth with mpc1 inhibitors
|
US10472364B2
(en)
|
2016-09-09 |
2019-11-12 |
Calithera Biosciences, Inc. |
Ectonucleotidase inhibitors and methods of use thereof
|
EP3939581A1
(en)
|
2016-09-09 |
2022-01-19 |
The Regents Of The University Of California |
Estrogen receptor ligands, compositions and methods related thereto
|
WO2018058029A1
(en)
|
2016-09-26 |
2018-03-29 |
Dana-Farber Cancer Institute, Inc. |
Chromobox protein inhibitors and uses thereof
|
EP4272761A3
(en)
|
2016-09-28 |
2024-01-03 |
Medicon Pharmaceuticals, Inc. |
Compositions for treating ophthalmic conditions
|
AU2017336765B2
(en)
|
2016-09-28 |
2023-06-08 |
Medicon Pharmaceuticals, Inc. |
Compositions and methods for treating ophthalmic conditions
|
MA46793A
(fr)
|
2016-11-08 |
2019-09-18 |
Calithera Biosciences Inc |
Polythérapies faisant appel à un inhibiteur d'arginase
|
ES2970715T3
(es)
|
2016-12-22 |
2024-05-30 |
Prec Pharmaceuticals Inc |
Composiciones y métodos para inhibir la actividad de la arginasa
|
ES2964985T3
(es)
|
2016-12-23 |
2024-04-10 |
Univ Leland Stanford Junior |
Compuestos sonda basados en actividad, composiciones y métodos de uso
|
WO2018136634A1
(en)
|
2017-01-18 |
2018-07-26 |
Vanderbilt University |
Fused heterocyclic compounds as selective bmp inhibitors
|
KR20190120786A
(ko)
|
2017-02-24 |
2019-10-24 |
메르크 파텐트 게엠베하 |
디히드로오로테이트 옥시게나제 억제제로서의 1,4,6-삼치환된-2-알킬-1H-벤조[d]이미다졸 유도체
|
SG11201908171TA
(en)
|
2017-03-31 |
2019-10-30 |
Aurigene Discovery Tech Ltd |
Compounds and compositions for treating hematological disorders
|
WO2018209288A1
(en)
|
2017-05-12 |
2018-11-15 |
Massachusetts Institute Of Technology |
Argonaute protein-double stranded rna complexes and uses related thereto
|
US11325943B2
(en)
|
2017-06-02 |
2022-05-10 |
Stealth Biotherapeutics Inc. |
Crystalline salt forms of SBT-20
|
CN110944634A
(zh)
|
2017-06-30 |
2020-03-31 |
加利福尼亚大学董事会 |
用于调节毛发生长的组合物和方法
|
EP3655379B1
(en)
|
2017-07-19 |
2023-04-05 |
California Institute of Technology |
Methods for preparing bis-tetrahydroisoquinoline-containing compounds
|
CN111194308A
(zh)
|
2017-10-11 |
2020-05-22 |
奥瑞基尼探索技术有限公司 |
3-取代的1,2,4-噁二唑的结晶形式
|
EA202090497A1
(ru)
|
2017-10-31 |
2020-11-23 |
Кьюрис, Инк. |
Соединения и композиции для лечения гематологических нарушений
|
US11497734B2
(en)
|
2017-11-03 |
2022-11-15 |
Aurigene Discovery Technologies Limited |
Dual inhibitors of TIM-3 and PD-1 pathways
|
EA202090749A1
(ru)
|
2017-11-06 |
2020-08-19 |
Ориджен Дискавери Текнолоджис Лимитед |
Способы совместной терапии для иммуномодуляции
|
CN111491922A
(zh)
|
2017-12-22 |
2020-08-04 |
免疫医疗有限公司 |
Keap1的BTB结构域的小分子调节剂
|
US10745400B2
(en)
|
2018-03-14 |
2020-08-18 |
Vanderbuilt University |
Inhibition of BMP signaling, compounds, compositions and uses thereof
|
EP3773614A1
(en)
|
2018-04-12 |
2021-02-17 |
Matrx Therapeutics Corporation |
Compositions and methods for treating elastic fiber breakdown
|
WO2019217450A1
(en)
|
2018-05-08 |
2019-11-14 |
Rhode Island Hospital |
Anti-chi3l1 antibodies for the detection and/or treatment of nonalcoholic fattly liver disease/nonalcoholic steatohepatitis and subsequent complications
|
EP3813841A4
(en)
|
2018-06-29 |
2022-03-09 |
The Regents Of The University Of California |
NEW MOLECULAR FORCEPS AGAINST NEUROLOGICAL DISORDERS AND VIRAL INFECTION
|
US20220106325A1
(en)
|
2018-07-27 |
2022-04-07 |
California Institute Of Technology |
Cdk inhibitors and uses thereof
|
AU2019336698A1
(en)
|
2018-09-05 |
2021-03-25 |
Aztherapies, Inc. |
Methods of treating cytokine release syndrome
|
CN114269345A
(zh)
|
2018-10-26 |
2022-04-01 |
科乐斯疗法公司 |
Alk2抑制剂的晶体形式
|
MA54261A
(fr)
|
2019-01-18 |
2022-04-27 |
Astrazeneca Ab |
Inhibiteurs de pcsk9 et leurs procédés d'utilisation
|
SG11202107145SA
(en)
|
2019-01-25 |
2021-08-30 |
Univ Brown |
Compositions and methods for treating, preventing or reversing age-associated inflammation and disorders
|
WO2020160323A2
(en)
|
2019-01-31 |
2020-08-06 |
Elektrofi, Inc. |
Particle formation and morphology
|
WO2020183021A1
(en)
|
2019-03-14 |
2020-09-17 |
Astrazeneca Ab |
Lanabecestat for weight loss
|
JP6890865B1
(ja)
|
2019-06-03 |
2021-06-18 |
株式会社大分大学先端医学研究所 |
狂犬病治療のための環状アミド化合物およびその方法
|
JP2022547546A
(ja)
|
2019-09-13 |
2022-11-14 |
エレクトロフィ,インコーポレイテッド |
疾患の処置のための治療用生物学的作用剤の送達のための組成物及び方法
|
BR112022009202A2
(pt)
|
2019-11-12 |
2022-09-06 |
Genzyme Corp |
Heteroarilaminosulfonamidas de 6 membros para tratamento de doenças e condições mediadas por atividade deficiente de cftr
|
WO2021113809A1
(en)
|
2019-12-05 |
2021-06-10 |
Genzyme Corporation |
Arylamides and methods of use thereof
|
WO2021113806A1
(en)
|
2019-12-05 |
2021-06-10 |
Genzyme Corporation |
Arylamides and methods of use thereof
|
US20230088747A1
(en)
|
2019-12-16 |
2023-03-23 |
Unist (Ulsan National Institute Of Science And Technology) |
Compounds for inhibiting neovascularization factors and use thereof
|
WO2021142221A1
(en)
|
2020-01-10 |
2021-07-15 |
The Regents Of The University Of California |
Compositions and methods for the treatment of neurodegenerative diseases
|
US20230094393A1
(en)
|
2020-02-07 |
2023-03-30 |
Elektrofi, Inc. |
Peptide particles and methods of formation
|
WO2021168271A1
(en)
|
2020-02-19 |
2021-08-26 |
Elektrofi, Inc. |
Droplet formation and particle morphology
|
JP2023522627A
(ja)
|
2020-04-17 |
2023-05-31 |
エレクトロフィ,インコーポレイテッド |
連続的な液滴形成及び脱水によって粒子を形成する方法
|
JP7519463B2
(ja)
|
2020-05-05 |
2024-07-19 |
ヌバレント, インク. |
ヘテロ芳香族大環状エーテル化学療法剤
|
WO2021263072A1
(en)
|
2020-06-25 |
2021-12-30 |
Dana-Farber Cancer Institute, Inc. |
Methods of treating disease
|
CN111830151B
(zh)
*
|
2020-07-01 |
2021-05-04 |
迪沙药业集团有限公司 |
盐酸安非他酮组合物质量控制用系统适用性对照品
|
CA3191166A1
(en)
|
2020-08-10 |
2022-02-17 |
Dana-Farber Cancer Institute, Inc. |
Substituted 3-amino-4-methylbenzenesulfonamides as small molecule inhibitors of ubiquitin-specific protease 28
|
US20230265082A1
(en)
|
2020-08-10 |
2023-08-24 |
Dana-Farber Cancer Institute, Inc. |
Substituted 1,2,4-oxadiazoles as small molecule inhibitors of ubiquitin-specific protease 28
|
CA3191163A1
(en)
|
2020-08-10 |
2022-02-17 |
Dana-Farber Cancer Institute, Inc. |
Fused tricyclic pyrimidine-thieno-pyridine small molecule inhibitors of ubiquitin-specific protease 28
|
US20230399304A1
(en)
|
2020-10-23 |
2023-12-14 |
Dana-Farber Cancer Institute, Inc. |
Covalent inhibitors of creatine kinase (ck) and uses thereof for treating and preventing cancer
|
US20240058344A1
(en)
|
2020-12-18 |
2024-02-22 |
Cornell University |
Methods of treating neurodegenerative disorders and stat3-linked cancers using suppressors of electron leak
|
EP4262880A1
(en)
|
2020-12-21 |
2023-10-25 |
Cornell University |
Peptide-linked drug delivery system
|
US20240132480A1
(en)
|
2021-01-08 |
2024-04-25 |
Cornell University |
Inhibitors of mycobacterium tuberculosis lipoamide dehydrogenase
|
TW202309022A
(zh)
|
2021-04-13 |
2023-03-01 |
美商努法倫特公司 |
用於治療具egfr突變之癌症之胺基取代雜環
|
EP4396176A1
(en)
|
2021-09-03 |
2024-07-10 |
Genzyme Corporation |
Indole compounds and uses thereof in the treatement of cystic fibrosis
|
WO2023034992A1
(en)
|
2021-09-03 |
2023-03-09 |
Genzyme Corporation |
Indole compounds and methods of use
|
KR20240087788A
(ko)
|
2021-10-01 |
2024-06-19 |
뉴베일런트, 아이엔씨. |
헤테로방향족 매크로사이클릭 에테르 화합물의 고체 형태, 약학 조성물 및 제조
|
KR20240095536A
(ko)
|
2021-10-01 |
2024-06-25 |
뉴베일런트, 아이엔씨. |
헤테로방향족 매크로사이클릭 에테르 화합물을 사용한 고형 종양의 치료 방법
|
WO2023187422A1
(en)
|
2022-03-31 |
2023-10-05 |
Revolo Biotherapeutics Limited |
Compositions and their use in methods for treating intestinal inflammation
|
TW202400608A
(zh)
|
2022-04-07 |
2024-01-01 |
美商努法倫特公司 |
雜芳族巨環醚化合物之固體形式、醫藥組合物及製備
|
WO2023196910A1
(en)
|
2022-04-07 |
2023-10-12 |
Nuvalent, Inc |
Methods of treating solid tumor using (19r)-5-chloro-3-ethyl-16-fluoro-10,19-dimethyl-20-oxa-3,4,10,11,23-pentaazapentacyclo[19.3.1.02,6.08,12.013,18]pentacosa-1(24),2(6),4,8,11,13,15,17,21(25),22-decaen-22-amine
|
WO2023212721A1
(en)
|
2022-04-29 |
2023-11-02 |
Elektrofi, Inc. |
Injectable suspensions
|
WO2023223015A1
(en)
|
2022-05-16 |
2023-11-23 |
Revolo Biotherapeutics Limited |
Methods and compositions for preventing or treating food allergies
|
WO2023250157A1
(en)
|
2022-06-24 |
2023-12-28 |
Cornell University |
Inhibitors of mycobacterium tuberculosis lipoamide dehydrogenase
|
WO2024013209A1
(en)
|
2022-07-13 |
2024-01-18 |
Astrazeneca Ab |
Pcsk9 inhibitors and methods of use thereof
|
WO2024036097A1
(en)
|
2022-08-12 |
2024-02-15 |
Nuvalent, Inc. |
Heteroaromatic macrocyclic ether compounds and isotopologues thereof
|
WO2024036098A1
(en)
|
2022-08-12 |
2024-02-15 |
Nuvalent, Inc. |
Heteroaromatic macrocyclic ether compounds
|
WO2024073334A1
(en)
|
2022-09-26 |
2024-04-04 |
Rose Research Center, Llc |
Combination for use in a method of preventing weight gain
|
WO2024086634A1
(en)
|
2022-10-19 |
2024-04-25 |
Nuvalent, Inc. |
Heteroaromatic macrocyclic ether chemotherapeutic agents
|